Live tape
Top 8, mentions 7d9,850TSLA2,037 mentions▲ +0.05GOOGL1,583 mentions▲ +0.04NVDA1,206 mentions▲ +0.07CRWV1,194 mentions▲ +0.03SPCX1,070 mentions▲ +0.07QQQ1,042 mentions▲ +0.04META873 mentions▲ +0.05NBIS845 mentions▲ +0.05

Equity · Healthcare

RCUS

NYSE

Arcus Biosciences, Inc.

$27.38 +1.41% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for RCUS to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $3.5B
52-week range $9 – $31.01
Avg volume 273.6K

as of Jul 17, 2026

RCUS insider trades

SEC Form 4 · last 90 days · newest reported trade 21 Aug 2026
Open-market buys 0
Open-market sells 1
Net sold $85K
Non-trade filings 1
Date Insider Type Shares Value
21 Aug 2026 Azoy Alexander Chief Accounting Officer Sell 2,827 $85K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
21 Aug 2026 Azoy Alexander Chief Accounting Officer Option exercise 2,827 $44K

RCUS reported financials

SEC EDGAR XBRL SEC EDGAR

RCUS reported revenue of $33.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$353.0M.

Figure Reported Period
Revenue $33.0M 31 Dec 2025 fiscal year
Net income −$353.0M 31 Dec 2025 fiscal year
Diluted EPS −$3.29 31 Dec 2025 fiscal year
Total assets $924.0M 30 Jun 2026 at period end
Total equity $464.0M 30 Jun 2026 at period end

RCUS earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.72 $41M
31 Mar 2026 Q1 2026 −$1.02 $17M
31 Dec 2025 FY 2025 −$3.29 $247M
30 Sep 2025 Q3 2025 −$1.27 $26M
30 Jun 2025 Q2 2025 $0.00 $160M
31 Mar 2025 Q1 2025 −$1.14 $28M
31 Dec 2024 FY 2024 −$3.14 $258M
30 Sep 2024 Q3 2024 −$1.00 $48M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

RCUS institutional holders

SEC Form 13F SEC EDGAR

10 of the 45 institutional funds we track reported a RCUS position for the quarter ended 30 Jun 2026 — a combined $282.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Citadel Advisors Added +135.7% shares 3,135,057 $96.7M
Fisher Asset Management Held (±25%) −2.3% shares 2,139,396 $66.0M
Marshall Wace Trimmed −48.3% shares 1,945,088 $60.0M
Baker Bros. Advisors Added +103.3% shares 844,816 $26.0M
Two Sigma Investments Added +103.2% shares 635,404 $19.6M
Man Group Added +70.4% shares 137,763 $4.2M
Millennium Management New position 133,110 $4.1M
D. E. Shaw & Co. Trimmed −62.8% shares 96,417 $3.0M
AQR Capital Management Held (±25%) −2.8% shares 83,861 $2.6M
Balyasny Asset Management New position 22,845 $704K

RCUS fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 1,065 shares of RCUS failed to deliver (about $27K).

Settlement date Shares failed Notional % of shares out
30 Sep 2026 1,065 $27K 0.001%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings